Möchten Sie immer auf dem neuesten Stand bleiben?

The case alleges Medpace oversold its projected book-to-bill ratio for fourth quarter 2025.

Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "COVID 19 - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. The report provides a detailed examination of over...

Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "Oligonucleotides - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. The report delves into the realm of...

CAMBRIDGE, United Kingdom and MONTREAL, April 13, 2026 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies...

Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly...

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Approval in CSU for children two to 11 years of age is...

Investors who lost money in IBRX after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.

WOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today...

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)